Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 8, 199 - 200 (2002)
doi:10.1038/nm0302-199b
Set back to Alzheimer vaccine studies
Karen Birmingham1 & Simon Frantz1
- London
Elan, the Ireland-based biotechnology company that had taken the lead in developing a potential vaccine to treat Alzheimer disease, has suffered a double set back. Within days of announcing that trials of its therapeutic vaccine, AN-1792, had been suspended, the company's share value plummeted by over 70% amid concerns over accounting practices and calls for Elan directors to resign.
To read this story in full you will need to login or make a payment (see right).
